Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. - Wikidata - awgldk - TriplyDB

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

http://www.wikidata.org/entity/Q37205811

about

ß1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination.

P2860

Q35005380-4913D217-1DB9-4C4A-97FB-C99A8FE74CBC Q49013708-8EAF7A3D-70FE-4185-B2A1-160A30DAFF12

P2860

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

http://www.wikidata.org/entity/Q37205811

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@en

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@nl

type

label

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@en

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@nl

prefLabel

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@en

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@nl

P1433

Q37205811-9EBC6D51-2E62-4D4D-85AA-9494163487B5

P1476

Q37205811-9467DEDD-A1FD-4D36-A97D-FA872B8B153A

P2093

Q37205811-36A64C5D-71B8-4A0E-9D48-8CBCC6C75424

Q37205811-D536D10D-9C25-49F9-B4E7-359D208350D6

P2860

Q37205811-004696F6-B4AD-4C45-80D6-F65AAE1CC3E5

Q37205811-02AF04A4-E208-461B-A9A0-C78560DFA3A2

Q37205811-03B145CD-2709-4E60-81DF-931263DF8681

Q37205811-05FDCAC3-A84D-40BD-BA19-73BB10993ABB

Q37205811-07EA0F1E-9B65-4102-AD15-CC79648DFA71

Q37205811-0A5A711A-21E9-4E0D-BEB7-A3A255EAD3B4

Q37205811-0C144542-0C31-47DB-81D5-D420B633972C

Q37205811-0D392C6F-7665-4296-98D4-E4A8182EBF84

Q37205811-146826C5-2866-4515-AF90-61A0642203FB

Q37205811-1EAC01A9-082C-4942-B38D-54073A17E814

P304

Q37205811-0413B14B-D8B9-422D-8C05-4C0A39B1B395

P31

Q37205811-36C4B253-B489-4464-B205-FA911F1B7850

P356

Q37205811-DAFD8EB8-2C63-4AFA-B802-527EAEFE4E42

P407

Q37205811-90B717E9-7E07-4EB9-8403-34CF531ADE64

P433

Q37205811-EC6A11E8-F1E5-47B1-9D16-6A0D68BA5283

P478

Q37205811-A3AF4402-BBDE-4DB4-A4FA-C29F0C066289

P577

Q37205811-EF0CCAA8-B019-4EFF-BD3B-14FC24543562

P698

Q37205811-DDB3C01F-B0C2-4BBB-A6A9-B1339D7C357D

P932

Q37205811-820EA436-43F2-46BD-888A-F1897C0FB55C

P356

P1433

Hospital Practice

P1476

Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

@en

P2093

Erin M Olson

http://www.w3.org/2001/XMLSchema#string

Senthilkumar Damodaran

http://www.w3.org/2001/XMLSchema#string

P2860

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

P304

7-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/HP.2012.10.997

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23299030

http://www.w3.org/2001/XMLSchema#string

P932

3786361

http://www.w3.org/2001/XMLSchema#string